S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biomark Diagnostics Inc. stock logo
BUX
Biomark Diagnostics
$0.00
$0.00
$0.00
N/AN/AN/A11,500 shs
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
$227.55
-1.1%
$253.64
$161.65
$275.00
$11.72B1.4550,575 shs707,817 shs
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biomark Diagnostics Inc. stock logo
BUX
Biomark Diagnostics
0.00%0.00%0.00%0.00%0.00%
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
-1.09%-7.11%-12.30%+11.54%+11.59%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Biomark Diagnostics Inc. stock logo
BUX
Biomark Diagnostics
N/AN/AN/AN/AN/AN/AN/AN/A
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
4.8822 of 5 stars
3.34.00.04.73.92.52.5

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Biomark Diagnostics Inc. stock logo
BUX
Biomark Diagnostics
N/AN/AN/AN/A
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
2.64
Moderate Buy$253.2311.29% Upside

Current Analyst Ratings

Latest IBX, BUX, BD1, and CRL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/18/2024
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$240.00 ➝ $290.00
2/15/2024
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$260.00 ➝ $265.00
2/15/2024
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$215.00 ➝ $250.00
2/15/2024
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$270.00 ➝ $290.00
2/15/2024
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$270.00 ➝ $280.00
2/15/2024
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$252.00 ➝ $268.00
2/15/2024
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral
(Data available from 4/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Biomark Diagnostics Inc. stock logo
BUX
Biomark Diagnostics
N/AN/AN/AN/AN/AN/A
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
$4.13B2.84$16.47 per share13.82$70.15 per share3.24

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Biomark Diagnostics Inc. stock logo
BUX
Biomark Diagnostics
N/AN/A0.00N/AN/AN/AN/AN/AN/A
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
$474.62M$9.2124.7118.401.8211.49%16.53%7.02%5/9/2024 (Confirmed)

Latest IBX, BUX, BD1, and CRL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/9/2024N/A
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
$2.05N/A-$2.05N/AN/AN/A  
2/14/2024Q4 2023
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
$2.39$2.46+$0.07$1.30$991.25 million$1.01 billion      

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Biomark Diagnostics Inc. stock logo
BUX
Biomark Diagnostics
N/AN/AN/AN/AN/A
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Biomark Diagnostics Inc. stock logo
BUX
Biomark Diagnostics
N/AN/AN/A
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
0.73
1.52
1.16

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Biomark Diagnostics Inc. stock logo
BUX
Biomark Diagnostics
N/A
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
98.91%

Insider Ownership

CompanyInsider Ownership
Biomark Diagnostics Inc. stock logo
BUX
Biomark Diagnostics
N/A
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
1.30%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Biomark Diagnostics Inc. stock logo
BUX
Biomark Diagnostics
N/AN/AN/ANot Optionable
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
21,80051.51 million50.84 millionOptionable

ACL, BUX, BD1, CRL, and CTE Headlines

SourceHeadline
Raymond James Financial Services Advisors Inc. Sells 31,134 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)Raymond James Financial Services Advisors Inc. Sells 31,134 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)
marketbeat.com - April 18 at 4:09 AM
Heres Why You Should Retain Charles River (CRL) Stock NowHere's Why You Should Retain Charles River (CRL) Stock Now
zacks.com - April 16 at 12:51 PM
Charles River Laboratories Launches Alternative Methods Advancement Project to Reduce Reliance on Animal TestingCharles River Laboratories Launches Alternative Methods Advancement Project to Reduce Reliance on Animal Testing
businesswire.com - April 16 at 8:00 AM
Flputnam Investment Management Co. Buys 4,293 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)Flputnam Investment Management Co. Buys 4,293 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)
marketbeat.com - April 15 at 5:36 PM
DekaBank Deutsche Girozentrale Boosts Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)DekaBank Deutsche Girozentrale Boosts Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)
marketbeat.com - April 13 at 5:50 AM
Charles River Laboratories International, Inc. (NYSE:CRL) Given Consensus Recommendation of "Moderate Buy" by AnalystsCharles River Laboratories International, Inc. (NYSE:CRL) Given Consensus Recommendation of "Moderate Buy" by Analysts
americanbankingnews.com - April 13 at 2:56 AM
ICLR or CRL: Which Is the Better Value Stock Right Now?ICLR or CRL: Which Is the Better Value Stock Right Now?
zacks.com - April 12 at 12:41 PM
Charles River Laboratories Schedules First-Quarter 2024 Earnings Release and Conference CallCharles River Laboratories Schedules First-Quarter 2024 Earnings Release and Conference Call
businesswire.com - April 12 at 8:00 AM
Sequoia Financial Advisors LLC Acquires 13,068 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)Sequoia Financial Advisors LLC Acquires 13,068 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)
marketbeat.com - April 12 at 6:36 AM
Charles River (CRL) Forges Collaboration With Ship of TheseusCharles River (CRL) Forges Collaboration With Ship of Theseus
zacks.com - April 11 at 10:10 AM
Charles River and Deciphex Launch Patholytix Foresight, a Transformative AI-Powered Decision Support Tool for Toxicologic PathologyCharles River and Deciphex Launch Patholytix Foresight, a Transformative AI-Powered Decision Support Tool for Toxicologic Pathology
businesswire.com - April 11 at 8:00 AM
Baillie Gifford & Co. Decreases Stock Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)Baillie Gifford & Co. Decreases Stock Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)
marketbeat.com - April 11 at 7:23 AM
Boston’s Charles River Is the Iconic Center of the Rowing UniverseBoston’s Charles River Is the Iconic Center of the Rowing Universe
wbsm.com - April 9 at 3:57 PM
Charles River To Collaborate With Axovia Therapeutics - Quick FactsCharles River To Collaborate With Axovia Therapeutics - Quick Facts
markets.businessinsider.com - April 9 at 10:45 AM
Charles River Announces Rare Disease Gene Therapy Collaboration with Axovia TherapeuticsCharles River Announces Rare Disease Gene Therapy Collaboration with Axovia Therapeutics
finance.yahoo.com - April 9 at 10:45 AM
Charles River Announces Rare Disease Gene Therapy Collaboration with Axovia TherapeuticsCharles River Announces Rare Disease Gene Therapy Collaboration with Axovia Therapeutics
businesswire.com - April 9 at 8:00 AM
Allspring Global Investments Holdings LLC Has $275.48 Million Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)Allspring Global Investments Holdings LLC Has $275.48 Million Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)
marketbeat.com - April 8 at 8:42 PM
Cambiar Investors LLC Raises Stake in Charles River Laboratories International, Inc. (NYSE:CRL)Cambiar Investors LLC Raises Stake in Charles River Laboratories International, Inc. (NYSE:CRL)
marketbeat.com - April 7 at 8:24 PM
DAVENPORT & Co LLC Makes New $1.90 Million Investment in Charles River Laboratories International, Inc. (NYSE:CRL)DAVENPORT & Co LLC Makes New $1.90 Million Investment in Charles River Laboratories International, Inc. (NYSE:CRL)
marketbeat.com - April 6 at 5:32 AM
International Assets Investment Management LLC Buys Shares of 97,870 Charles River Laboratories International, Inc. (NYSE:CRL)International Assets Investment Management LLC Buys Shares of 97,870 Charles River Laboratories International, Inc. (NYSE:CRL)
marketbeat.com - April 5 at 2:28 PM
Riverbridge Partners LLC Sells 14,387 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)Riverbridge Partners LLC Sells 14,387 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)
marketbeat.com - April 5 at 12:49 AM
Charles River to Perform Plasmid Production for Ship of TheseusCharles River to Perform Plasmid Production for Ship of Theseus
businesswire.com - April 4 at 8:00 AM
Charles River to Perform Plasmid Production for Ship of TheseusCharles River to Perform Plasmid Production for Ship of Theseus
businesswire.com - April 4 at 8:00 AM
Regency Capital Management Inc. DE Buys Shares of 15,665 Charles River Laboratories International, Inc. (NYSE:CRL)Regency Capital Management Inc. DE Buys Shares of 15,665 Charles River Laboratories International, Inc. (NYSE:CRL)
marketbeat.com - April 3 at 10:15 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Biomark Diagnostics logo

Biomark Diagnostics

CNSX:BUX
BioMark Diagnostics Inc., an oncology focused company, develops cancer diagnostic solutions to detect, monitor, and assess early treatment. It has a collaborative research agreement with the Icahn School of Medicine for clinical studies related to early lung cancer diagnosis. The company was incorporated in 2014 and is headquartered in Richmond, Canada. BioMark Diagnostics Inc. is a subsidiary of Biomark Technologies Inc.
Charles River Laboratories International logo

Charles River Laboratories International

NYSE:CRL
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.